{"product_id":"bio-techne-business-model-canvas","title":"Bio-Techne Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne Business Model Canvas: Clear Strategy, Fast Decisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Bio-Techne’s business model—our downloadable Business Model Canvas lays out customer segments, value propositions, revenue streams, and key partnerships in a concise, actionable format; ideal for investors, consultants, and entrepreneurs seeking clear, ready-to-use insights to benchmark strategy and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne uses global distribution agreements to extend reach in Europe and the Gulf, citing a 12% revenue lift in EMEA in 2024; partners sell products without Bio-Techne adding manufacturing overhead.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Bio-Techne began distributing Spear Bio’s ultrasensitive immunoassays for Alzheimer’s across its network, expected to add ~$8–12M ARR and strengthen neurodegeneration research offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Academic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne keeps deep ties with universities and research centers that act as customers and co‑innovators; for example, the company licenses platforms such as SPEAR from Harvard, giving it early access to novel assays and IP that boosted R\u0026amp;D-driven sales—academic sales accounted for roughly 18% of revenue in 2024 (~$230M of $1.28B total)—so these alliances sustain product leadership and pipeline feed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma and Biotech Co-Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne co-develops with major pharma and biotech firms, supplying custom reagents and GMP-grade proteins for clinical use; as of late 2025 over 550 customers use its GMP reagents, with several programs in Phase II\/III, driving recurring revenue—GMP sales contributed roughly 18% of 2024 revenue (~$220M of $1.22B) and position products inside commercial manufacturing workflows for next-gen therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Manufacturing Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Techne secures high-purity inputs for R\u0026amp;D Systems and Tocris by contracting specialized protein-expression and small-molecule synthesis vendors, ensuring consistency that supports \u0026gt;95% lot-release pass rates reported in 2024.\u003c\/p\u003e\n\u003cp\u003ePartnerships now prioritize supply-chain resilience and regional production—Bio-Techne expanded local sourcing to cover ~30% of critical reagents in 2024 to reduce tariff and trade-risk exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized vendors for proteins and small molecules\u003c\/li\u003e\n\u003cli\u003eMaintains \u0026gt;95% lot-release pass rate (2024)\u003c\/li\u003e\n\u003cli\u003e~30% critical-reagent local sourcing (2024)\u003c\/li\u003e\n\u003cli\u003eFocus on resilience, tariff and trade-risk mitigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Investment and M\u0026amp;A Targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Techne follows a buy-and-build approach, taking minority stakes—eg, its 2023 minority investment in Wilson Wolf—then completing full acquisitions to expand cell and gene therapy capabilities; by end-2025 these partnerships are expected to supply ~15–20% of new product pipeline value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuy-and-build: minority stake then acquisition\u003c\/li\u003e\n\u003cli\u003eExample: Wilson Wolf minority deal 2023\u003c\/li\u003e\n\u003cli\u003eEnd-2025 pipeline contribution est. 15–20%\u003c\/li\u003e\n\u003cli\u003eDe-risks tech entry while funding global scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne: Diverse channels, strong GMP recurring revenue \u0026amp; resilient supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne leverages global distributors, academic licenses, pharma co-development, and targeted M\u0026amp;A to drive channel reach, R\u0026amp;D feed and recurring GMP revenue—academic sales ~18% ($230M) and GMP ~18% ($220M) of 2024 revenue; Spear Bio deal adds ~$8–12M ARR (2025); supply resilience: \u0026gt;95% lot-pass, ~30% local sourcing (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic licensing\u003c\/td\u003e\n\u003ctd\u003e18% rev, $230M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP\/co-dev\u003c\/td\u003e\n\u003ctd\u003e18% rev, $220M (2024); 550+ customers (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e12% EMEA lift (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic deals\u003c\/td\u003e\n\u003ctd\u003eSpear Bio $8–12M ARR (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply resilience\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95% lot-pass; 30% local sourcing (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Bio-Techne that maps customer segments, channels, value propositions, key activities, partners, resources, cost structure and revenue streams with narrative insights and SWOT-linked competitive analysis to support presentations, funding discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Bio-Techne’s business model with editable cells to quickly pinpoint value drivers, streamline product-to-market pathways, and save hours on structuring strategic analyses for boardrooms or team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Biotechnology Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne runs GMP-grade facilities for large-scale recombinant proteins, antibodies, and high-purity small molecules, supplying research and clinical markets; in 2025 it expanded U.K. GMP capacity and introduced the ProPAX form factor, raising manufacturing throughput by ~15% and supporting revenue-backed supply contracts worth \u0026gt;$120m annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne reinvests ~8% of revenue into R\u0026amp;D and launched over 500 new products in fiscal 2025, prioritizing AI-enhanced designer proteins and next-gen automated instruments like the Leo Simple Western system to tackle complex biology; this sustained R\u0026amp;D spend and product velocity supports leadership in proteomics and spatial biology and underpins recurring revenue growth and margin resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Portfolio Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManagement sharpened the portfolio by divesting Exosome Diagnostics in 2025, reallocating capital and R\u0026amp;D toward higher-margin, non-CLIA product lines to boost profitability.\u003c\/p\u003e\n\u003cp\u003eThe move targets streamlined ops and a higher EBITDA mix; management cites a path to a 40% long-term EBITDA margin, with FY2024 pro forma margins improving by ~350 basis points after early-stage divestitures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-Techne runs global sales and marketing to reach biopharma, academia, and diagnostics, investing in Customer Experience Centres like the Düsseldorf lab opened in 2024 to demo instruments and shorten sales cycles; Q3 2025 reported instrument revenue growth of ~12% year-over-year. \u003c\/p\u003e\n\u003cp\u003eDedicated technical support teams onboard and integrate platforms such as COMET and Ella into workflows, reducing implementation time by ~30% and lowering service churn; service contracts contributed about 18% of 2024 revenue. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew Düsseldorf centre opened 2024\u003c\/li\u003e\n\u003cli\u003eInstrument revenue +12% YoY (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eSupport cuts implementation time ~30%\u003c\/li\u003e\n\u003cli\u003eService contracts ≈18% of 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and quality assurance ensure Bio-Techne products meet CE-IVD and GMP standards, a continuous process essential for clinical market access and trust.\u003c\/p\u003e\n\u003cp\u003eIn early 2026 the Ella platform achieved CE-IVD marking in Europe, expanding diagnostic use; QA spans design, validation, manufacturing, packaging, and distribution to support reliable clinical decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCE-IVD for Ella: achieved Q1 2026\u003c\/li\u003e\n\u003cli\u003eGMP-covered sites: 8 global facilities\u003c\/li\u003e\n\u003cli\u003eAnnual QA audits: ~120 across suppliers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne: 8 GMP sites, 500+ 2025 launches, Ella CE‑IVD, \u0026gt;$120M supply, 40% EBITDA target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne operates 8 GMP sites, reinvests ~8% of revenue in R\u0026amp;D, launched 500+ products in 2025, and grew instrument revenue ~12% YoY (Q3 2025); service contracts ≈18% of 2024 revenue and Ella achieved CE-IVD in Q1 2026, supporting \u0026gt;$120m annual supply contracts and a management target of 40% long-term EBITDA.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D reinvestment\u003c\/td\u003e\n\u003ctd\u003e~8% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew products 2025\u003c\/td\u003e\n\u003ctd\u003e500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument rev growth Q3 2025\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contracts (2024)\u003c\/td\u003e\n\u003ctd\u003e~18% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElla CE‑IVD\u003c\/td\u003e\n\u003ctd\u003eQ1 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply contracts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$120m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget long‑term EBITDA\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Bio-Techne Business Model Canvas document—not a mockup or summary—and it reflects the exact content and layout you’ll receive after purchase; upon ordering, you’ll instantly get this full, ready-to-edit file in the same professional format for use in presentations, analysis, or sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749135987065,"sku":"bio-techne-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bio-techne-business-model-canvas.png?v=1772213186","url":"https:\/\/matrixbcg.com\/products\/bio-techne-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}